In GeparTrio, the largest study evaluating the prognostic value of post-NAC Ki67 index in breast cancer, three groups of patients (1151 patients in total; 484 with pCR and 667 with RD) were established based on Ki67: the low Ki67 group (0–15%), the medium Ki67 group (15.1–35%), and the high Ki67 group (>35.1%). This evidence concerns the gene MKI67 and breast carcinoma.